Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
Pre-Market: $204.76 0.00 (0.00%) 8:20 AM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
Pre-Market: $204.76 0.00 (0.00%) 8:20 AM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific
3 Tech Stocks for Growth Investors to Buy Right Now
by Benjamin Rains
Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Top Research Reports for Chubb, Las Vegas Sands & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chubb (CB), Las Vegas Sands (LVS) and Biogen (BIIB).
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid
by Zacks Equity Research
Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.
5 Low Price-to-Book Value Stocks for Great Returns
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.
PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
Biotech ETFs in Focus on String of Q1 Earnings Beats
by Sweta Jaiswal, FRM
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are earnings releases by most leading biotech entities.
What's in the Cards for Sunesis (SNSS) This Earnings Season?
by Zacks Equity Research
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
3 Tech Stocks for Growth Investors to Buy Right Now
by Benjamin Rains
Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.
Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
Biogen (BIIB) Q1 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beat estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
What's in Store for Celgene Corporation (CELG) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
by Zacks Equity Research
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed the most recent trading day at $237.58, moving -0.9% from the previous trading session.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Celgene Gets Positive CHMP Nod for Revlimid Label Expansion
by Zacks Equity Research
Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.